3SBio Gains China Rights to Pegylated Chemotherapy from JenKem

3SBio, a Shenyang-based biopharma, acquired an exclusive China license from JenKem Technology of China to develop, manufacture and market JenKem's pegylated form of irinotecan, a chemotherapy. Irinotecan inhibits topoisomerase I (Topo-I), which is over-expressed in many solid tumors. Initially, 3SBio will develop PEG-irinotecan for metastatic colorectal cancer and breast cancer, as well as platinum-resistant ovarian cancer. Financial details were not disclosed. More details.... Share this with colleagues: // //